Pando Bioscience
Gen-AI Designed Enzymes for Pharmaceutical Innovation
Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
Active Founders
Will Cao
Will Cao is the co-founder and CEO of Pando Bioscience. During her Ph.D., Will changed her major from engineering machines to engineering bacteria (yes, making genetic modifications to bacteria, so they can produce things that they can't before). She has published first-author papers in Cell and Nature Biotechnology. In her spare time, she is a personal trainer and a kayak and scuba diving enthusiast.
Yang Wang
Yang is the co-founder and CTO of Pando Bioscience. Experienced in enzyme science, bioinformatics, machine learning, systems biology, genetics and high-throughput automation. Worked at Ginkgo Bioworks for three years and routinely discovered/designed enzymes with tens-to-thousands-fold improvements. Trained at Dana-Farber Cancer Institute and deeply studied the relationships between protein-protein interactions and human diseases.
Company Launches
Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for pharma. Our ultra-high-throughput screening platform screens 1000 times more enzymes, 75% faster, and 80% cheaper than traditional methods. This empowers our generative AI to optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that cut costs and enhance efficiency.
The Problem
Enzymes play a crucial role in driving market growth and profitability in the pharmaceutical industries. Inefficient or underutilized enzymes can lead to significant financial losses and missed opportunities. Therefore, developing optimized enzymes that possess a balance of key properties becomes a top priority but remains challenging and time-consuming.
Our Solution
Our AI model designs enzymes with specific mutations that enhance multiple properties simultaneously. These AI-generated enzymes are tested using our unique ultra-high-throughput one-pot screening platform. This platform converts diverse biological signals into abundant and quantifiable data under various conditions. By integrating AI design with advanced screening, we’ve reduced the design-build-test-learn cycle to just one month. We efficiently evaluate enzyme performance across different criteria tackling the challenge of multi-property optimization.
At Pando, we help pharma companies improve existing enzymes and discover new ones, cutting costs and boosting productivity. We are also developing our own proprietary enzyme assets.
Our Team
We are experts in the field. @Will joined the synthetic biology unicorn Ginkgo Bioworks as an early employee. @Yang spent 6 years at Harvard Medical School before joining Ginkgo. AI-guided enzyme engineering is in our wheelhouse.
Want to be part of it?
If you are from a pharma, diagnostic, or biotech company and are interested in taking enzyme engineering to the next level, please don't hesitate to reach out to us at founders@pando.bio.
Thank you!
YC Sign Photo
